PR Newswire·Oct 14, 2025, 7:00 AM ET

Caristo Chosen by Leading Pharma Company as Worldwide Imaging Core Lab to Measure Coronary Plaque and Inflammation

Caristo Diagnostics serves as the worldwide imaging core lab for NewAmsterdam Pharma's REMBRANDT clinical trial.
The trial utilizes Caristo's CaRi-Heart® and CaRi-Plaque™ technologies to measure & monitor coronary inflammation & plaque.
REMBRANDT is a placebo-controlled, double-blind, randomized trial assessing the efficacy of obicetrapib & ezetimibe fixed dose combination (FDC) on coronary plaque burden.
The study recruits patients from 50 sites across 7 countries: United States, Poland, United Kingdom, Czech Republic, Hungary, Italy, & Spain.
The primary efficacy outcome is the percent change in noncalcified coronary atherosclerotic plaque volume (NCPV) from baseline to 18 months via coronary computed tomographic angiography (CCTA).
Secondary endpoints include absolute NCPV changes, LDL-C changes, & the perivascular fat attenuation index (FAI-Score™), a proprietary biomarker for coronary inflammation.
Caristo's responsibilities include certifying & training clinical sites, conducting baseline & follow-up analyses at 6 & 18 months, & ensuring rigorous image quality control & data anonymization.
Obicetrapib is an investigational cholesteryl ester transfer protein (CETP) inhibitor that has demonstrated LDL-C lowering in three Phase 3 clinical trials.